Infiniti was founded by clinicians, engineers, and dreamers who believed that technology could enhance the practice of veterinary medicine. Today, Infiniti not only produces solutions for a myriad of common conditions, but also scalable technologies in education, diagnostics, and telemedicine. Infiniti believes in the vast opportunity for its solutions to enhance the veterinary ecosystem.
We Create Elegant Solutions for Everyday Problems
Solving problems requires an attentive ear, domain expertise, and creativity. We are an amalgamation of clinicians, engineers, and designers who collaborate to connect the dots and harvest the best of Silicon Valley. Our holistic approach provides veterinarians all over the world solutions that have disrupted the clinical care environment.
The Infiniti odyssey began by creating novel solutions for a handful of problematic clinical issues. Our cutting-edge Vet Stent technology fundamentally redefined treatments for airway disease, vascular disease, and urinary obstruction. The lessons learned from the development of these solutions lead to the broader ambition of creating a platform approach to address issues veterinarians face in treating patients and running their practices. Today Infiniti not only offers solutions for a broad range of clinical conditions, but also supplements them with scalable efforts in education, telemedicine, and diagnostics. Looking to tomorrow, Infiniti is currently investing in many areas including digital health and technology with the promise to enhance patient encounters in practices on a global scale.
Co-Founder and CEO
Jared is Co-Founder and CEO of Infiniti. His goal is to establish the premier animal health platform offering cutting-edge technologies for the treatment of companion animals.
Today, Infiniti has introduced unique solutions to veterinary hospitals in over thirty countries worldwide, cementing its position as the global leader within the animal health technology field.
Utilizing his extensive finance and animal health experience, Jared is responsible for guiding Infiniti’s worldwide strategic growth efforts from its headquarters in Silicon Valley. In 2018, Jared led the acquisition of Orthomed (UK) Ltd, thereby expanding Infiniti’s footprint throughout Europe and Asia.
Jared began his career at Credit Suisse First Boston in Palo Alto, advising on corporate transactions as a member of the firm’s top-ranked Technology Investment Banking Group. Following Credit Suisse, he worked at Rothschild Inc. in New York City, focusing on mergers & acquisitions.
Jared earned an MBA with honors from The Wharton School of the University of Pennsylvania in 2002 (part of the elite sub-matriculation program), and graduated cum laude with a B.S. in Economics from The Wharton School in 2001, with dual concentrations in finance and management.
Dr. Sarit Dhupa
Chief Medical Officer
Sarit is Chief Medical Officer of Infiniti. Sarit has spent almost three decades in both academic and private practice veterinary medicine on three continents. Most recently, he retired as President of California Veterinary Specialists, a group of multidisciplinary, 24-hour tertiary care specialty veterinary hospitals which were acquired by the Mars group in 2017.
Sarit’s goal is to foster the mission of Infiniti which is to provide innovative and novel technologies to veterinarians worldwide. His focus is on building out Infiniti’s global training platform as well as driving new product development initiatives. This is done through an extensive collaboration with biomedical engineers, physicians and veterinary professionals.
Sarit comes from a background of advanced anesthesia and surgical training obtained in academic institutions in both Europe and the United States. He is a Diplomate of the American College of Veterinary Surgeons.
Dr. Thomas J. Fogarty
Board Member & Emeritus Director of Strategy and Innovation
Dr. Thomas J. Fogarty is an internationally recognized cardiovascular surgeon, inventor, entrepreneur, and investor. He has been involved with a wide spectrum of innovations in business and technology, serving as founder/co-founder, and Chairman/board member of over 30 medical device companies, the majority based on devices designed and developed by Fogarty Engineering, Inc.
Dr. Fogarty has published approximately 180 scientific articles and textbook chapters in fields of general and cardiovascular surgery,and is the author or co-author of more than 125 patents and patent applications.His patents include the “industry standard” Fogarty balloon embolectomy catheter (now owned by Edwards Lifesciences), and the widely used Aneurx Stent Graft (now owned by Medtronic). Dr. Fogarty is the recipient of countless awards and honors; most significantly, he is the recipient of the Jacobson Innovation Award of the American College of Surgeons, the 2000 Lemelson-MIT prize for Invention and Innovation and was inducted into the Inventors Hall of Fame in December 2001 and The National Academy of engineering. Dr. Fogarty is currently Adjunct Clinical Professor of Surgery at Stanford University.